vs
Arcellx, Inc.（ACLX）与Bio-Techne（TECH）财务数据对比。点击上方公司名可切换其他公司
Bio-Techne的季度营收约是Arcellx, Inc.的178.9倍（$295.9M vs $1.7M）。Bio-Techne净利率更高（12.8% vs -3513.4%，领先3526.3%）。Bio-Techne同比增速更快（-6.4% vs -89.2%）。过去两年Bio-Techne的营收复合增速更高（4.2% vs -79.5%）
Arcellx, Inc.是一家处于临床阶段的生物技术企业，专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法，其核心管线针对肿瘤领域未被满足的医疗需求，服务全球患者群体。
Bio-Techne是美国头部生命科学企业，面向科研、诊断及生物工艺市场需求，研发、生产并销售生命科学试剂、仪器及配套服务，产品及解决方案广泛应用于基础研究、体外诊断、生物医药研发生产等场景，可为相关领域从业者提供可靠的专业工具支持。
ACLX vs TECH — 直观对比
营收规模更大
TECH
是对方的178.9倍
$1.7M
营收增速更快
TECH
高出82.7%
-89.2%
净利率更高
TECH
高出3526.3%
-3513.4%
两年增速更快
TECH
近两年复合增速
-79.5%
损益表 — Q4 2025 vs Q2 2026
| 指标 | | |
|---|---|---|
| 营收 | $1.7M | $295.9M |
| 净利润 | $-58.1M | $38.0M |
| 毛利率 | — | 64.6% |
| 营业利润率 | -3850.2% | 18.4% |
| 净利率 | -3513.4% | 12.8% |
| 营收同比 | -89.2% | -6.4% |
| 净利润同比 | -23.4% | 68.3% |
| 每股收益（稀释后） | $-1.01 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ACLXTECH
| Q4 25 | $1.7M | $295.9M | ||
| Q3 25 | $4.9M | — | ||
| Q2 25 | $7.6M | $317.0M | ||
| Q1 25 | $8.1M | $316.2M | ||
| Q4 24 | $15.3M | $297.0M | ||
| Q3 24 | $26.0M | $289.5M | ||
| Q2 24 | $27.4M | $306.1M | ||
| Q1 24 | $39.3M | $303.4M |
净利润ACLXTECH
| Q4 25 | $-58.1M | $38.0M | ||
| Q3 25 | $-55.8M | — | ||
| Q2 25 | $-52.8M | $-17.7M | ||
| Q1 25 | $-62.3M | $22.6M | ||
| Q4 24 | $-47.1M | $34.9M | ||
| Q3 24 | $-25.9M | $33.6M | ||
| Q2 24 | $-27.2M | $40.6M | ||
| Q1 24 | $-7.2M | $49.1M |
毛利率ACLXTECH
| Q4 25 | — | 64.6% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 62.7% | ||
| Q1 25 | — | 67.9% | ||
| Q4 24 | — | 65.3% | ||
| Q3 24 | — | 63.2% | ||
| Q2 24 | — | 66.4% | ||
| Q1 24 | — | 67.4% |
营业利润率ACLXTECH
| Q4 25 | -3850.2% | 18.4% | ||
| Q3 25 | -1248.3% | — | ||
| Q2 25 | -777.4% | -7.5% | ||
| Q1 25 | -847.6% | 12.2% | ||
| Q4 24 | -348.2% | 16.0% | ||
| Q3 24 | -129.1% | 13.8% | ||
| Q2 24 | -127.8% | 15.0% | ||
| Q1 24 | -40.3% | 22.1% |
净利率ACLXTECH
| Q4 25 | -3513.4% | 12.8% | ||
| Q3 25 | -1127.1% | — | ||
| Q2 25 | -698.6% | -5.6% | ||
| Q1 25 | -766.0% | 7.1% | ||
| Q4 24 | -308.4% | 11.7% | ||
| Q3 24 | -99.4% | 11.6% | ||
| Q2 24 | -99.3% | 13.3% | ||
| Q1 24 | -18.3% | 16.2% |
每股收益（稀释后）ACLXTECH
| Q4 25 | $-1.01 | $0.24 | ||
| Q3 25 | $-0.99 | — | ||
| Q2 25 | $-0.94 | $-0.11 | ||
| Q1 25 | $-1.13 | $0.14 | ||
| Q4 24 | $-0.87 | $0.22 | ||
| Q3 24 | $-0.48 | $0.21 | ||
| Q2 24 | $-0.51 | $0.26 | ||
| Q1 24 | $-0.14 | $0.31 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $450.3M | $172.9M |
| 总债务越低越好 | — | $260.0M |
| 股东权益账面价值 | $402.4M | $2.0B |
| 总资产 | $604.0M | $2.5B |
| 负债/权益比越低杠杆越低 | — | 0.13× |
8季度趋势，按日历期对齐
现金及短期投资ACLXTECH
| Q4 25 | $450.3M | $172.9M | ||
| Q3 25 | $461.4M | — | ||
| Q2 25 | $453.1M | $162.2M | ||
| Q1 25 | $543.3M | $140.7M | ||
| Q4 24 | $587.4M | $177.5M | ||
| Q3 24 | $574.3M | $187.5M | ||
| Q2 24 | $516.7M | $152.9M | ||
| Q1 24 | $573.9M | $145.3M |
总债务ACLXTECH
| Q4 25 | — | $260.0M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $346.0M | ||
| Q1 25 | — | $330.0M | ||
| Q4 24 | — | $300.0M | ||
| Q3 24 | — | $300.0M | ||
| Q2 24 | — | $319.0M | ||
| Q1 24 | — | $389.0M |
股东权益ACLXTECH
| Q4 25 | $402.4M | $2.0B | ||
| Q3 25 | $440.8M | — | ||
| Q2 25 | $392.2M | $1.9B | ||
| Q1 25 | $416.9M | $2.0B | ||
| Q4 24 | $454.8M | $2.1B | ||
| Q3 24 | $483.0M | $2.1B | ||
| Q2 24 | $487.2M | $2.1B | ||
| Q1 24 | $496.6M | $2.0B |
总资产ACLXTECH
| Q4 25 | $604.0M | $2.5B | ||
| Q3 25 | $655.9M | — | ||
| Q2 25 | $619.1M | $2.6B | ||
| Q1 25 | $648.1M | $2.6B | ||
| Q4 24 | $711.3M | $2.7B | ||
| Q3 24 | $764.9M | $2.7B | ||
| Q2 24 | $734.3M | $2.7B | ||
| Q1 24 | $779.7M | $2.7B |
负债/权益比ACLXTECH
| Q4 25 | — | 0.13× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | 0.18× | ||
| Q1 25 | — | 0.16× | ||
| Q4 24 | — | 0.14× | ||
| Q3 24 | — | 0.14× | ||
| Q2 24 | — | 0.15× | ||
| Q1 24 | — | 0.19× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-58.2M | — |
| 自由现金流经营现金流 - 资本支出 | $-58.9M | — |
| 自由现金流率自由现金流/营收 | -3563.4% | — |
| 资本支出强度资本支出/营收 | 46.2% | — |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-212.6M | — |
8季度趋势，按日历期对齐
经营现金流ACLXTECH
| Q4 25 | $-58.2M | — | ||
| Q3 25 | $-49.2M | — | ||
| Q2 25 | $-39.7M | $98.2M | ||
| Q1 25 | $-63.1M | $41.1M | ||
| Q4 24 | $-46.0M | $84.3M | ||
| Q3 24 | $30.7M | $63.9M | ||
| Q2 24 | $-36.2M | $75.5M | ||
| Q1 24 | $-31.9M | $81.0M |
自由现金流ACLXTECH
| Q4 25 | $-58.9M | — | ||
| Q3 25 | $-49.5M | — | ||
| Q2 25 | $-40.2M | $93.3M | ||
| Q1 25 | $-63.9M | $31.0M | ||
| Q4 24 | $-47.5M | $77.5M | ||
| Q3 24 | $28.4M | $54.7M | ||
| Q2 24 | $-39.5M | $57.5M | ||
| Q1 24 | $-38.3M | $64.5M |
自由现金流率ACLXTECH
| Q4 25 | -3563.4% | — | ||
| Q3 25 | -1000.3% | — | ||
| Q2 25 | -532.4% | 29.4% | ||
| Q1 25 | -786.4% | 9.8% | ||
| Q4 24 | -311.3% | 26.1% | ||
| Q3 24 | 109.2% | 18.9% | ||
| Q2 24 | -144.1% | 18.8% | ||
| Q1 24 | -97.7% | 21.3% |
资本支出强度ACLXTECH
| Q4 25 | 46.2% | — | ||
| Q3 25 | 6.0% | — | ||
| Q2 25 | 6.4% | 1.5% | ||
| Q1 25 | 9.6% | 3.2% | ||
| Q4 24 | 9.8% | 2.3% | ||
| Q3 24 | 8.8% | 3.2% | ||
| Q2 24 | 11.7% | 5.9% | ||
| Q1 24 | 16.4% | 5.4% |
现金转化率ACLXTECH
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 1.82× | ||
| Q4 24 | — | 2.42× | ||
| Q3 24 | — | 1.90× | ||
| Q2 24 | — | 1.86× | ||
| Q1 24 | — | 1.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ACLX
暂无分部数据
TECH
| Diagnostics And Spatial Biology | $81.2M | 27% |
| EMEA Excluding UK | $75.4M | 25% |
| Other | $42.4M | 14% |
| Instruments | $29.6M | 10% |
| APAC Excluding Greater China | $22.7M | 8% |
| Services | $22.3M | 8% |
| GB | $13.7M | 5% |
| Royalty | $8.5M | 3% |
